发明名称 |
HUMAN CANCER THERAPY USING ENGINEERED MATRIX METALLOPROTEINASE-ACTIVATED ANTHRAX LETHAL TOXIN THAT TARGETS TUMOR VASCULATUTURE |
摘要 |
The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis.
|
申请公布号 |
US2010168012(A1) |
申请公布日期 |
2010.07.01 |
申请号 |
US20070519362 |
申请日期 |
2007.12.14 |
申请人 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF |
发明人 |
LEPPLA STEPHEN H.;LIU SHIHUI;BUGGE THOMAS H.;CURIE BROOKE M. |
分类号 |
A61K38/16;A61P35/00 |
主分类号 |
A61K38/16 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|